Physician profile
Daniel L Holt
NPI 1922003375
$29,689.60
in general payments reported to CMS, 2019-2025
53 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,516 · 2020: $5,856 · 2021: $13K · 2022: $613 · 2023: $1,434 · 2024: $1,591 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,642.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18,984.67 | 2020-2025 | Glassia, Gammagard |
| Shire North American Group INC | $5,339.94 | 2019 | |
| Novo Nordisk INC | $635.15 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $548.32 | 2021-2025 | |
| Lilly USA, LLC | $509.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $466.31 | 2020-2025 | |
| Amgen INC. | $447.42 | 2019-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $330.35 | 2020-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $198.92 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $160.69 | 2019-2024 | Farxiga, Airsupra |
| Medtronic USA, INC. | $142.00 | 2019 | |
| Exact Sciences Corporation | $130.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $114.59 | 2022-2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $113.26 | 2023-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.88 | 2023-2025 | Stiolto Respimat, Spiriva Respimat, Jardiance |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $95.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $89.01 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $86.14 | 2024-2025 | Zenpep |
| Sanofi Pasteur INC. | $83.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $75.85 | 2023-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Vifor Pharma, INC. | $70.15 | 2024-2025 | Veltassa, Zemaira |
| Astellas Pharma US INC | $67.86 | 2025 | Veozah |
| Insulet Corporation | $59.36 | 2023-2025 | Omnipod |
| Alkermes, INC. | $56.52 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $55.12 | 2021 | |
| Sumitomo Pharma America, INC. | $48.19 | 2024 | Myfembree, Gemtesa |
| Xeris Pharmaceuticals, INC. | $47.48 | 2023-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $47.27 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $42.39 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $36.40 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $33.44 | 2025 | |
| Tonix Medicines, INC. | $31.25 | 2025 | Tonmya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.06 | 2023 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $30.95 | 2023 | Dupixent |
| Indivior INC. | $29.38 | 2023 | Sublocade |
| Pulmonx Corporation | $28.53 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Janssen Biotech, INC. | $28.07 | 2025 | Tremfya |
| Corcept Therapeutics | $26.21 | 2022 | |
| Edwards Lifesciences Corporation | $24.85 | 2020 | |
| Csl Behring | $24.01 | 2025 | Hizentra |
| Medtronic, INC. | $23.77 | 2024 | Venaseal |
| Boston Scientific Corporation | $20.40 | 2022 | |
| Axonics, INC. | $18.70 | 2023 | Axonics |
| Genzyme Corporation | $17.82 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $17.44 | 2025 | Neffy |
| Eisai INC. | $17.14 | 2024 | |
| Baxter Healthcare | $16.53 | 2022 | |
| Esperion Therapeutics, INC. | $15.97 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $14.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2024 | Camzyos |
| Horizon Therapeutics Plc | $13.97 | 2023 | Krystexxa |
| Noven Therapeutics, LLC | $13.45 | 2024 | Xelstrym, Secuado |
| Biohaven Pharmaceuticals, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.